2018
DOI: 10.1136/neurintsurg-2018-013765
|View full text |Cite
|
Sign up to set email alerts
|

Thrombectomy using the EmboTrap device: core laboratory-assessed results in 201 consecutive patients in a real-world setting

Abstract: The Embotrap device has a high rate of successful reperfusion. Our core laboratory-audited single-center experience suggests the technical feasibility and safety of the Embotrap for first-line use in a real-world setting.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
14
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(17 citation statements)
references
References 38 publications
2
14
1
Order By: Relevance
“…These recanalization results are slightly higher compared to data from studies with the sole use of Trevo (68.8% TICI ≥ 2b, TRACK registry), a recent core laboratory-audited single-center experience and a previous multicenter series with the sole use of EmboTrap (71.1% and 73% TICI ≥ 2b, respectively). [15][16][17][18] The rate of excellent final reperfusion (mTICI ≥ 2c) by the exclusive use of APH was 71.0% (22/31) in the present study and was comparable to recanalization rate of the AP with 75% (15/20) (mTICI ≥ 2c) and was slightly superior to the recanalization rates of 64.7% mTICI ≥ 2c in the ARISE-II study (64.7%) for EmboTrap. 19 First-pass recanalization rate mTICI ≥ 2b for the solely use of the APH was comparable to the EmboTrap in the recent published ARISE II trial (APH, 58.1% vs. Embo-Trap, 51.5%).…”
Section: Discussionsupporting
confidence: 42%
See 1 more Smart Citation
“…These recanalization results are slightly higher compared to data from studies with the sole use of Trevo (68.8% TICI ≥ 2b, TRACK registry), a recent core laboratory-audited single-center experience and a previous multicenter series with the sole use of EmboTrap (71.1% and 73% TICI ≥ 2b, respectively). [15][16][17][18] The rate of excellent final reperfusion (mTICI ≥ 2c) by the exclusive use of APH was 71.0% (22/31) in the present study and was comparable to recanalization rate of the AP with 75% (15/20) (mTICI ≥ 2c) and was slightly superior to the recanalization rates of 64.7% mTICI ≥ 2c in the ARISE-II study (64.7%) for EmboTrap. 19 First-pass recanalization rate mTICI ≥ 2b for the solely use of the APH was comparable to the EmboTrap in the recent published ARISE II trial (APH, 58.1% vs. Embo-Trap, 51.5%).…”
Section: Discussionsupporting
confidence: 42%
“…from other non-RCT stent retriever studies ranging between 15% and 28%. [16][17][18][19] The rate of FO after 3 months (mRS 0-2) was 44.0% (11/25)…”
Section: Correlation With Aphmentioning
confidence: 99%
“…Studies of patients treated with the recent EmboTrap stent-retriever system were not included. Although some data from registries [20][21][22] showed promising results, no comparative data are available on clinical outcomes between the EmboTrap system and Solitaire or Trevo stent retrievers. Studies of patients with anterior circulation occlusion and concomitant cervical carotid occlusion (tandem occlusion) were not excluded.…”
Section: Methodsmentioning
confidence: 99%
“…Brouwer et al have published their long experience in mechanical thrombectomy using both EmboTrap and EmboTrap II systems showing slightly better results in terms of successful reperfusion rates (84.6%) but a comparable clinical outcome (52.8%). 23 Anyhow, the use of EmboTrap II seemed technically feasible and safe and the reperfusion rates shown are comparable to that of other devices such as Trevo 21 and Solitaire. 1…”
Section: Discussionmentioning
confidence: 64%
“…have published their long experience in mechanical thrombectomy using both EmboTrap and EmboTrap II systems showing slightly better results in terms of successful reperfusion rates (84.6%) but a comparable clinical outcome (52.8%). 23…”
Section: Discussionmentioning
confidence: 99%